Searchable abstracts of presentations at key conferences in endocrinology

ea0052p39 | (1) | UKINETS2017

A case of carcinoid crisis despite high dose somatostatin analogue therapy peri-operatively

Pitfield Deborah , Casey Ruth , Seetho Ian , Shaw Ashley , Buscombe John , Roe Paul , Buczacki Simon , Challis Ben

Introduction: Carcinoid crisis is a life threatening endocrine emergency. It remains unclear whether there is an optimal dose of prophylactic somatostatin analogue (SSA) therapy in the peri-operative periodCase Study: A 62 year old lady with a new diagnosis of metastatic carcinoid disease was electively admitted for a right hemicolectomy for a well differentiated neuroendocrine tumour in the terminal ileum. A multi-disciplinary decision was made to offer...

ea0038oc5.3 | Thyroid and parathyroid | SFEBES2015

Use of 11C-methionine PET to localise parathyroid adenoma/hyperplasia: a single centre experience

Challis Ben , Saad Ziauddin , Cheow H K , Buscombe John , Simpson Helen

Introduction: It is established practice to localise parathyroid lesions preoperatively using ultrasound (US) and sestaMIBI (MIBI). Whilst these imaging techniques have good sensitivity/specify, there are patients in which imaging does not localise a parathyroid lesion. 11C-Methionine PET (MET PET) is an imaging modality where 11C-methionine, a radioactive tracer, is taken up at sites of protein/peptide synthesis and has been demonstrated to be effective ...

ea0044p135 | Neoplasia, cancer and late effects | SFEBES2016

The effect of peptide receptor radionuclide therapy (PRRT) on symptoms and tumour burden in patients with metastatic neuroendocrine tumour (NET)

Abraham Stalin , Casey Ruth , Challis Ben , Pitfield Deborah , Whitley S , Shaw Ashley , Heard Sarah , Saad Zia , Buscombe John , Simpson Helen

Peptide receptor radionuclide therapy (PRRT) is a targeted therapy using synthetic somatostatin analogues attached to a radionuclide, which binds to tumours expressing somatostatin receptors. The aim was to review the role of PRRT in a tertiary referral centre. We retrospectively reviewed a cohort of 25 patients (eight males, 17 females), with a median age of 65, who received Yttrium-90 DOTATATE or Lutetium-177 DOTATATE at Addenbrookes Hospital. The location of the primary tum...

ea0034p365 | Steroids | SFEBES2014

11C-metomidate PET–CT in primary hyperaldosteronism: a valuable alternative to AVS

Powlson Andrew S , Koulouri Olympia , Challis Benjamin G , Cheow H K , Buscombe John , Koo Brendan , Brown Morris J , Gurnell Mark

Although adrenal vein sampling (AVS) remains the gold-standard for distinguishing unilateral and bilateral disease in primary hyperaldosteronism (PHA), it is technically demanding and not always feasible. Metomidate (MTO), a potent inhibitor of CYP11B1 and CYP11B2, can be C11H3-labelled as a PET tracer (11C-MTO), and we have previously shown it to be an alternative to AVS for localising unilateral aldosterone-producing adenomas (APAs) (Burton <...

ea0037oc1.4 | Adrenal 1 | ECE2015

11C-metomidate PET-CT in primary aldosteronism: five possible indications for a non-invasive alternative to adrenal vein sampling

Powlson Andrew S , Koulouri Olympia , Azizan Elena , Maniero Carmela , Taylor Kevin , Aigbirhio Franklin , Koo Brendan , Cheow Heok K , Buscombe John , Gurnell Mark , Brown Morris J

Background: Adrenal vein sampling (AVS) remains the gold-standard for distinguishing unilateral and bilateral disease in primary aldosteronism (PA). However, it is invasive, technically demanding, and may yield inconclusive or equivocal results. 11C-Metomidate PET-CT (11C-MTO-PET-CT) is a non-invasive alternative to AVS for localising unilateral aldosterone-producing adenomas (APAs).Methods/patients: We report a retrospective analys...

ea0031p165 | Neoplasia, cancer and late effects | SFEBES2013

Audit of patients with multiple endocrine neoplasia type 1 in a tertiary referral centre

Goudie Calum , Reddy Snigdha , Parker Victoria , Curran Suzanne , Corrie Pippa , Shaw Ashley , Jamieson Neville , Praseedom Raaj , Huget Emmanuel , Jah Asif , Carroll Nicolas , Buscombe John , Park Soo-Mi , Simpson Helen

Aim: To review the presentation, management and outcomes in adult patients with MEN1 attending a multidisciplinary clinic.Methods: Case notes and electronic records were reviewed in patients attending a tertiary centre clinic for care of MEN1.Results: Forty-eight patients were analysed; 46% were male and 54% female. Mean age was 49 years (range 14–89) and 4% were deceased. Eighty-five percent had confirmed MEN1 mutations and 2...